CordenPharma has officially announced a major escalation of its global manufacturing footprint, committing to an €80 million ($93 million) multi-year investment program at its state-of-the-art facility in Caponago, Italy. This strategic expansion is designed to address the tightening supply chain for parenteral and sterile drug products, providing a significant boost to the company’s ability to support complex injectable therapeutics.
The centerpiece of this announcement is the acquisition of a new 11,000 m² commercial building situated on 26,000 m² of land adjacent to CordenPharma’s existing aseptic fill-and-finish site. Finalized on July 26, 2026, the deal increases the total Caponago footprint by more than 50%. This acquisition provides a “blank canvas” for the company to offer highly tailored, fit-for-purpose CDMO services for a variety of complex modalities, including peptides, lipid nanoparticles (LNPs), small molecules, biologics, and oligonucleotides.
By integrating these new capabilities with existing LNP manufacturing infrastructure already on the same campus, CordenPharma aims to offer a unified, single-site solution for innovators. The new facility has been master-planned to accommodate a minimum of four additional aseptic fill-and-finish lines, four visual inspection stations, and four secondary packaging lines. This space also offers the flexibility for customer-owned production lines, large-scale lyophilization, and dedicated auto-injector assembly.
Parallel to this physical site expansion, CordenPharma is finalizing immediate capacity upgrades within its existing operational zones. Over the past two years, the company has been installing two advanced aseptic fill-and-finish isolator lines to meet surging demand. These include a Bausch & Ströbel line dedicated to clinical and small-scale commercial production of pre-filled syringes (PFS), vials, and cartridges, alongside a high-speed Syntegon line engineered for PFS and cartridges capable of outputting more than 500,000 units per day. To support this heightened production volume, the company is also doubling its analytical capacity and expanding its automated secondary packaging area. Completion of these new isolator lines is slated for 2027 and 2028.
“This strategic investment strengthens our leadership in the manufacture of drug products using complex modalities and enhances our end-to-end supply capabilities to meet rising global demand for injectable outsourcing,” said Dr. Michael Quirmbach, President & CEO of CordenPharma Group. “Ultimately, this enables our partners to bring vital drug products in key therapeutic areas to patients more efficiently.”
Industry experts note that as the pharmaceutical landscape shifts toward high-concentration injectables and advanced delivery systems like auto-injectors, manufacturers face significant technical hurdles in sterile production. With the Caponago site’s total production capacity projected to reach 500 million units per year, CordenPharma is positioning itself as a critical partner for global innovators, supporting the entire lifecycle of a drug product—from early-phase clinical development to high-volume commercial scale-up.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
